NASDAQ:IKNA Ikena Oncology (IKNA) Stock Price, News & Analysis $1.69 -0.01 (-0.59%) (As of 09/10/2024 ET) Add Compare Share Share Today's Range$1.68▼$1.7050-Day Range$1.60▼$1.8552-Week Range$1.02▼$4.95Volume17,324 shsAverage Volume297,737 shsMarket Capitalization$81.56 millionP/E RatioN/ADividend YieldN/APrice Target$3.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Ikena Oncology alerts: Email Address Ikena Oncology MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside77.5% Upside$3.00 Price TargetShort InterestHealthy1.06% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.03) to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.63 out of 5 starsMedical Sector408th out of 899 stocksBiological Products, Except Diagnostic Industry56th out of 154 stocks 3.3 Analyst's Opinion Consensus RatingIkena Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIkena Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Ikena Oncology's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.06% of the float of Ikena Oncology has been sold short.Short Interest Ratio / Days to CoverIkena Oncology has a short interest ratio ("days to cover") of 1.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ikena Oncology has recently decreased by 10.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldIkena Oncology does not currently pay a dividend.Dividend GrowthIkena Oncology does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for IKNA. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Ikena Oncology to their MarketBeat watchlist in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ikena Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.94% of the stock of Ikena Oncology is held by insiders.Percentage Held by Institutions75.00% of the stock of Ikena Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ikena Oncology's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Ikena Oncology are expected to grow in the coming year, from ($1.03) to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ikena Oncology is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ikena Oncology is -1.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIkena Oncology has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ikena Oncology's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Timothy SykesHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloading stocks at an incredible pace… But I’m not worried at all… Because I don’t hold stocks… Instead I trade in and out of them using a simple strategy that works in bull markets and bear markets. I’ll be breaking down this strategy in a free live broadcast on Thursday, September 12 at 6 PM ET, where I’ll also be giving away $100,000 in gifts to active attendees.Sign up for free here. About Ikena Oncology Stock (NASDAQ:IKNA)Ikena Oncology, Inc. operates as an oncology company that develops differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the United States. Its lead program is IK-930, an internally discovered, oral, TEAD1-selective, small molecule inhibitor of the Hippo pathway. The company also develops IK-595, a molecular glue designed to trap MEK and RAF in an inactive complex. Ikena Oncology, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.Read More IKNA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IKNA Stock News HeadlinesAugust 10, 2024 | finanznachrichten.deIkena Oncology, Inc.: Ikena Oncology Reports Second Quarter 2024 Financial ResultsAugust 8, 2024 | globenewswire.comIkena Oncology Reports Second Quarter 2024 Financial ResultsSeptember 11, 2024 | Timothy Sykes (Ad)How to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloading stocks at an incredible pace… But I’m not worried at all… Because I don’t hold stocks… Instead I trade in and out of them using a simple strategy that works in bull markets and bear markets. I’ll be breaking down this strategy in a free live broadcast on Thursday, September 12 at 6 PM ET, where I’ll also be giving away $100,000 in gifts to active attendees.May 29, 2024 | msn.comWedbush downgrades Ikena, cites discontinuation of lead assetMay 29, 2024 | msn.comIkena Oncology Discontinues IK-930 Program And Cuts Workforce, Analyst Calls It 'Disappointing'May 29, 2024 | msn.comThis American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For WednesdayMay 28, 2024 | marketwatch.comIkena Oncology to Cut Half of Workforce, Discontinue Development of CandidateMay 28, 2024 | msn.comIkena to cut workforce by 53%, explore strategic optionsSeptember 11, 2024 | Timothy Sykes (Ad)“Why I don’t care if the Fed cuts rates” - SYKES In on Friday out by Monday Over the past decade I’ve made millions of dollars with a strategy I call Weekend Trading. It’s the best strategy I know of - because it revolves around making a quick trade right before the market closes on Friday afternoon… And closing the trade when the market opens the following Monday.May 28, 2024 | globenewswire.comUPDATE – Ikena Oncology Announces Strategic UpdateMay 28, 2024 | globenewswire.comIkena Oncology Announces Strategic UpdateMay 13, 2024 | investorplace.comIKNA Stock Earnings: Ikena Oncology Beats EPS for Q1 2024May 13, 2024 | globenewswire.comIkena Oncology Reports First Quarter 2024 Financial Results and Corporate UpdateApril 21, 2024 | finance.yahoo.comIkena Oncology, Inc. (IKNA)April 10, 2024 | globenewswire.comIkena Oncology to Present at the Stifel 2024 Virtual Targeted Oncology ForumMarch 19, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On Ikena OncologyMarch 14, 2024 | finance.yahoo.comIkena Oncology Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 13, 2024 | markets.businessinsider.comIkena Oncology’s Promising Drug Pipeline Merits a Buy RatingSee More Headlines Receive IKNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ikena Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/11/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IKNA CUSIPN/A CIK1835579 Webikenaoncology.com Phone857-273-8343FaxN/AEmployees70Year FoundedN/APrice Target and Rating Average Stock Price Target$3.00 High Stock Price Target$4.00 Low Stock Price Target$2.00 Potential Upside/Downside+77.5%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-68,170,000.00 Net MarginsN/A Pretax Margin-10,149.09% Return on Equity-40.71% Return on Assets-34.40% Debt Debt-to-Equity RatioN/A Current Ratio18.22 Quick Ratio18.22 Sales & Book Value Annual Sales$9.16 million Price / Sales8.90 Cash FlowN/A Price / Cash FlowN/A Book Value$3.52 per share Price / Book0.48Miscellaneous Outstanding Shares48,260,000Free Float45,391,000Market Cap$81.56 million OptionableNot Optionable Beta0.48 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesDr. Mark Manfredi Ph.D. (Age 53)President, CEO & Director Comp: $810.69kDr. Jotin Marango M.D. (Age 45)Ph.D., CFO & Head of Corporate Development Comp: $577.12kMr. Bob LallySenior Vice President of Finance & OperationsMs. Srividya Subramanian Esq.Ph.D., VP & Deputy General CounselMs. Samantha VuksanicHead of Human ResourcesMr. Jeffrey Ecsedy Ph.D. (Age 54)Chief Development Officer Mr. Navin Parwani M.S.VP & Head of QualityMr. David Damphousse M.S.Senior Vice President of Clinical Development OperationsDr. Caroline Germa M.D. (Age 52)Ph.D., Chief Medical Officer Mr. Valdas Jurkauskas Ph.D.Senior Vice President of Technical OperationsMore ExecutivesKey CompetitorsSpero TherapeuticsNASDAQ:SPROVor BiopharmaNYSE:VORInventivaNASDAQ:IVAXilio TherapeuticsNASDAQ:XLOFoghorn TherapeuticsNASDAQ:FHTXView All CompetitorsInstitutional OwnershipBlue Owl Capital Holdings LPBought 200,000 shares on 8/15/2024Ownership: 8.478%Point72 Asia Singapore Pte. Ltd.Bought 45,520 shares on 8/15/2024Ownership: 0.094%AQR Capital Management LLCBought 21,861 shares on 8/15/2024Ownership: 0.045%Marshall Wace LLPSold 43,758 shares on 8/14/2024Ownership: 0.093%Vanguard Personalized Indexing Management LLCBought 18,310 shares on 8/12/2024Ownership: 0.038%View All Institutional Transactions IKNA Stock Analysis - Frequently Asked Questions How have IKNA shares performed this year? Ikena Oncology's stock was trading at $1.97 at the start of the year. Since then, IKNA stock has decreased by 14.2% and is now trading at $1.69. View the best growth stocks for 2024 here. How were Ikena Oncology's earnings last quarter? Ikena Oncology, Inc. (NASDAQ:IKNA) issued its quarterly earnings results on Thursday, August, 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.04. When did Ikena Oncology IPO? Ikena Oncology (IKNA) raised $125 million in an initial public offering (IPO) on Friday, March 26th 2021. The company issued 7,800,000 shares at $15.00-$17.00 per share. Jefferies, Cowen, Credit Suisse and William Blair served as the underwriters for the IPO. Who are Ikena Oncology's major shareholders? Top institutional shareholders of Ikena Oncology include Blue Owl Capital Holdings LP (8.48%), Renaissance Technologies LLC (0.99%), Sofinnova Investments Inc. (0.79%) and Acadian Asset Management LLC (0.67%). Insiders that own company stock include Venture Fund Xi LP Atlas, Jean Francois Formela and Xiaoyan Michelle Zhang. View institutional ownership trends. How do I buy shares of Ikena Oncology? Shares of IKNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:IKNA) was last updated on 9/11/2024 by MarketBeat.com Staff From Our PartnersFREE TRAINING TODAY ➡️ How to profit from 2024 electionEarlier this year, Millionaire Trader Nate Bear of Monument Traders Alliance went live in front of thousands o...Monument Traders Alliance | SponsoredHow to grow a small trading account into a $100k? Why is Warren Buffett dumping stocks? Billionaires like Warren Buffett, Tim Cook, and Jeff Bezos are offloa...Timothy Sykes | SponsoredKamala’s Promise Will Kill America (Revealed)Kamala’s 3-Word Plan to Destroy America — Are You Prepared? Discover the secret plan that will bankrupt eve...Banyan Hill Publishing | SponsoredWarning For Nvidia HoldersHow The Boeing Disasters Could Hit Nvidia Investors You may have heard about Boeing planes falling apart mi...Stansberry Research | SponsoredWall St. Icon: Looming Financial Tsunami will Wipe Out the 1%Wall Street icon who forecasted Black Monday and dot-com crash says a new economic event will hit the American...InvestorPlace | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinA shocking leak has revealed Japanese electronics giant Sony is now starting its own blockchain. This move ...Crypto 101 Media | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredIt’s over.We found a tiny company which provides the backbone for the entire $15.7 trillion AI industry... It's used ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ikena Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ikena Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IKNA Stock Alerts